TrialReader


Effects of an Amino Acid Mixture on Gastrointestinal Function, Inflammation and Fluid Balance: A Pilot Study in Patients With Inflammatory Bowel Disease

NCT03451253 — Not applicable, Terminated, 7 participants, Entrinsic Bioscience Inc.

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Effects of an Amino Acid Mixture Versus a Sugar Based Sports Drink on Gastrointestinal Function, Inflammation and Fluid Balance: A Pilot Study in Patients With Inflammatory Bowel Disease

RegistryNCT03451253
StatusTerminated - Suboptimal accrual
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: triple, other
Enrollment7 (Actual)
SponsorEntrinsic Bioscience Inc. (Industry)
ConditionsInflammatory Bowel Diseases, Short Bowel Syndrome, Ileostomy - Stoma
Interventionsamino acid mixture beverage, glucose-based sports drink (Other)
Datesstart 2018-04-12, primary completion 2021-03-23, completion 2021-03-23, first posted 2018-03-01, last updated 2023-03-23
Locations3 sites in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Inflammatory Bowel Diseases All trials for Short Bowel Syndrome All trials of amino acid mixture beverage All trials of glucose-based sports drink

-Summary

This pilot study will examine the benefit of this amino acid based hydration solution in patients with IBD who have undergone a total colectomy and have either ileostomies or jpouches. Findings from this study and possible future studies could have broad implications for patients with malabsorption resulting from many underlying conditions, including IBD.

Expand all sections  ·  Collapse all

+Detailed description

This pilot study will examine the benefit of this amino acid based hydration solution in patients with IBD who have undergone a total colectomy and have either ileostomies or jpouches. Findings from this study and possible future studies could have broad implications for patients with malabsorption resulting from many underlying conditions, including IBD.

+Arms and interventions

ArmTypeInterventionsDescription
amino acid mixture beverageExperimentalOther: amino acid mixture beverageamino acid based hydration beverage. It will be given 8 oz, twice daily for the first 4 weeks of randomized blinded intervention. It will be given in same dose during 4 week open label intervention.
glucose based sports drinkActive comparatorOther: glucose-based sports drinkglucose based hydration beverage. It will be given 8oz, twice daily for the first 4 weeks of randomized blinded intervention.
  • amino acid mixture beverage (Other), also known as enterade: commercially available amino acid mixture. Contains 5 amino acids, electrolytes and natural flavoring.
  • glucose-based sports drink (Other), also known as Gatorade: Commercially available glucose-based sports drink, contains electrolytes, sugar and artificial flavoring.

+Outcome measures

Primary outcomes

  • GI output [total 8 weeks]: Change in GI output over a 24 hour period as the average of the 3 days every week for two different periods of 4 weeks

Secondary outcomes

  • Fluid Balance [8 weeks]: Fluid balance - intake vs output
  • Tolerability of Drink [8 weeks]: Taste perception Survey
  • Quality of Life Index [8 weeks]: Inflammatory Bowel Disease Questionnaire (IBDQ)
  • Quality of Life Index [8 weeks]: SF-36 Questionnaire
  • Changes in Blood [8 weeks]: mm Hg
  • Changes in heart rate [8 weeks]: Beats per minute
  • Changes in Lactulose-Mannitol Test [8 weeks]: The standard test for leaky gut syndrome
  • Immune Response based on Cytokine Levels [8 weeks]

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

1. Colectomy with ileostomy

   a. Ileostomy alone with less than 30 cm of small bowel resected i. A diverting ileostomy is permitted
2. Stable disease activity with no or mild inflammation felt not to significantly impact gastrointestinal (GI) output.
3. Any of the following:

   1. Need for IV fluids >2x/month
   2. Intake of > 1.5 liters of oral fluid daily
4. GI output of > 1.3 liters in a 24-hour period for three days each week during a 14 day screening period (does not need to be consecutive days)
5. Stable doses of anti-diarrheal agents, octreotide or Gattex
6. Stable doses of anti-inflammatory agents and/or antibiotics
7. Willing to comply with study visits and assessments, including product intake.

Exclusion:

1. Chronic renal insufficiency glomerular filtration rate (GFR) < 40
2. Significant chronic liver disease altering fluid balance
3. Uncontrolled flare of inflammatory disease

   a. (Inflammation can be present but at a stable at least partly controlled level) b. An anticipated change in medication in the next 3 months i. May be included 8 weeks after changing medications if they are stable c. Anticipated gastrointestinal surgery in the subsequent 3 months i. May be included if they are 4 months out from surgery and stable
4. Diabetes
5. Use of Lactulose/Mannitol solution is contraindicated
6. Current Diagnosis of Cancer

   a. May be included if they are 4 or more months out from cancer therapy (i.e. chemotherapy, etc.)
7. Aversion to the taste of enterade® or inability to take the product as instructed

+Locations (3)

FacilityCityCountryStatus
Brighan and Women's HospitalBoston, MassachusettsUnited States
Dartmouth-HitchcockNashua, New HampshireUnited States
University of North CarolinaChapel Hill, North CarolinaUnited States

My Notes